Successful subcutaneous desensitization in a patient with systemic reaction due to ixekizumab

Ixekizumab is a high-affinity IgG4 monoclonal humanized antibody indicated for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy. We describe the case of a 54-female patient with HLAB27+ spondyloarthritis. The patient experienced immediate severe dyspnea, skin erythema and flushing after ixekizumab administration. Our 8-step protocol desensitization to ixekizumab was safe and effective enabling the patient to maintain the best therapeutical option for her.